IP Library Granted Patent US 12,622,967
Granted Patent B2
US 12,622,967 · App. 18/668,190 · Granted May 12, 2026

Molecules, formulations, and methods for nutritional support of athletes, patients, and others

Inventors: George A. Brooks (Seattle, WA); Michael A. Horning (San Francisco, CA); Iñigo San Millán (Littleton, CO)
Assignee: Today, Inc.
A61K47/10A23L33/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,622,967
App. No.
18/668,190
Granted
May 12, 2026
Kind
B2
Abstract

The present invention relates to nutritional formulations for increasing sports and other physical performance and that have beneficial effects on health and wellness for various populations. The invention includes molecular compounds as disclosed. A preferred embodiment is a molecule type based on a glycerol backbone, with three glycerol functional groups B 1 , B 2 , B 3 , wherein one or more of the B groups may correspond to one of the functional energy groups A 1 , A 2 or A 3 , as disclosed. The invention includes nutritional formulations, some based on the inventive molecular compounds. The invention also includes method of using, administering, and implementing the above, including computer implemented and computer assisted methods.

Claims (8)

1 . A molecule, as shown:

wherein functional group B 1 comprises beta hydroxybutyrate, functional group B 2 comprises beta hydroxybutyrate and functional group B 3 comprises lactate or pyruvate.

2 . An aqueous formulation comprising: a molecule, as shown:

wherein functional group B 1 comprises beta hydroxybutyrate, functional group B 2 comprises beta hydroxybutyrate and functional group B 3 comprises lactate or pyruvate.

3 . The formulation of claim 2 further comprising an aqueous nutritional formulation for humans or mammals or both.

4 . The formulation of claim 2 wherein the formulation is suitable for administration by one or more of the following: intravenously, enterally, orally.

5 . The formulation of claim 2 wherein the formulation is hypertonic.

6 . The formulation of claim 2 wherein the formulation is isotonic.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2024
From: HORNING, MICHAEL; BROOKS, GEORGE; SAN MILLÁN, IÑIGO
To: TODAY, INC.
Reel/Frame 067458/0124 →
Continuity (3)
Continuation 18096794 · Jan 13, 2023
Provisional Application 63300563 · Jan 18, 2022
Related Publication 20240299548A1 · Sep 12, 2024
References Cited (5)
US 6743821B2 · Brooks · 2004 [cited by examiner]
US 7807718B2 · Hashim · 2010 [cited by examiner]
US 10792269B2 · Hashim · 2020 [cited by examiner]
US 20230151395A1 · Lochmann · 2023 [cited by examiner]
White et al. (A Systematic Review of Intravenous ß-Hydroxybutyrate Use in Humans—A Promising Future Therapy? Front Med (Lausanne). Sep. 21, 2021;8:740374. doi: 10.3389/fmed.2021.740374. PMID: 34621766; PMCID: PMC8490680… [cited by examiner]